Table of Contents
“Trumpcare” and Health Insurance Markets: A Tale of Two Timelines for Repeal and Replace
Two scenarios for how repeal and replace changes might unfold.
What President-Elect Trump’s Unexpected Win Means for BioPharma
The election results sent biopharma stock soaring. Breaking down what’s really on tap for biopharma over the next four years.
Calculating ‘Value’ In Healthcare
New standards for data interoperability could redefine the value proposition for payers, providers, and patients.
Building a Health Equity Framework for the Pharmaceutical Sector
Merck executives share their strategy for embedding health equity across the pharma value chain.
